Epilepsy

Condition Description

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations and sometimes loss of awareness.

Active Trials

  • TRIAL TITLE: A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension.

    DESCRIPTION: PRAX-562-221 is a Phase 2, multicenter, double-blind, randomized clinical trial, followed by an open-label extension (OLE), and is designed to explore the safety, tolerability, efficacy, and PK of PRAX-562 when administered to pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.

    SPONSOR: Praxis Precision Medicines

    INDICATION: Developmental Epileptic Encephalopathies

    STUDY PROTOCOL: PRAX-562-22

    PHASE: 2

    STATUS: Active

    RECRUITING PATIENTS: No

    Inquire About This Trial →

  • TRIAL TITLE: A Phase 2, Prospective, Interventional, Open-Label, Multisite, Extension Study To Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome.

    DESCRIPTION: This is a multisite, open-label extension (OLE) study designed to obtain additional safety and tolerability data related to soticlestat (also known as TAK-935) administered long-term in subjects with developmental and epileptic encephalopathies who participated in a previous soticlestat clinical study. Additional aims are to explore the long-term effects of soticlestat on seizure frequency and to assess the effects of soticlestat on quality-of-life measures. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study.

    Study treatments may continue as long as the participant is receiving benefit from it.

    SPONSOR: Takeda Development Center Americas, Inc.

    INDICATION: Developmental Epileptic Encephalopathies including Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome.

    STUDY PROTOCOL: TAK-935-18-001

    PHASE: 2

    STATUS: Active

    RECRUITING PATIENTS: No